Compare RR & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | DSGN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.2M | 579.9M |
| IPO Year | 2023 | 2021 |
| Metric | RR | DSGN |
|---|---|---|
| Price | $5.45 | $10.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 32.2M | 342.7K |
| Earning Date | 01-20-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $147.00 | N/A |
| Revenue Next Year | $37.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.37 | $2.60 |
| 52 Week High | $7.43 | $10.97 |
| Indicator | RR | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.03 | 60.71 |
| Support Level | $3.81 | $9.66 |
| Resistance Level | $4.85 | $10.97 |
| Average True Range (ATR) | 0.52 | 0.78 |
| MACD | 0.12 | 0.09 |
| Stochastic Oscillator | 93.18 | 79.07 |
Richtech Robotics Inc is a developer of new robotic technologies focused on transforming labor-intensive services in hospitality and other sectors currently experiencing unprecedented labor shortages. The company designs, manufacture and sells robots to restaurants, hotels, senior living centers, casinos, factories, movie theaters and other businesses. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company designs its robots to be friendly, customizable to client environments, and extremely reliable.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.